GlassScriptPhysician profile
Thomas R Stross
NPI 1811391063
$4,193.58
in general payments reported to CMS, 2019-2025
17 companies · $1,809 in 2025
The $1,809 reported for 2025 was more than what 91% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $35.40 · 2023: $1,503 · 2024: $847 · 2025: $1,809.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,158.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,158.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $765.21 | 2023-2025 | Ingrezza |
| Alkermes, INC. | $567.23 | 2023-2025 | Lybalvi, Aristada, Vivitrol |
| Vanda Pharmaceuticals INC. | $519.65 | 2023-2025 | Fanapt, Hetlioz |
| Teva Pharmaceuticals USA, INC. | $471.90 | 2023-2025 | Austedo Xr, Uzedy, Austedo Xr |
| Abbvie INC. | $399.90 | 2023-2025 | |
| Otsuka America Pharmaceutical, INC. | $316.72 | 2023-2025 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $234.83 | 2023-2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $230.15 | 2021-2024 | Invega Sustenna, Invega Trinza |
| E.R. Squibb & Sons, L.L.C. | $187.70 | 2025 | Cobenfy |
| Lundbeck LLC | $119.79 | 2024-2025 | Rexulti |
| Novo Nordisk INC | $114.57 | 2025 | Ozempic |
| Indivior INC. | $89.74 | 2023-2024 | Perseris |
| Supernus Pharmaceuticals, INC. | $61.22 | 2023-2025 | Qelbree, Qelbree |
| Orexo US, INC. | $53.58 | 2023-2024 | Zubsolv |
| Hologic Sales and Service, LLC | $25.78 | 2024 | Aptima, Thinprep 2000 Processor |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Luye Pharma (USA) LTD. | $21.71 | 2025 | Erzofri Extended-Release |
| Sage Therapeutics, LLC | $13.90 | 2025 | Zurzuvae |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Stross listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.